University of 91Ö±²¥ spinout company Crucible Therapeutics raises £5 million to advance pioneering treatments for neurological diseases
University of 91Ö±²¥ spinout company, Crucible Therapeutics, a biotechnology company developing novel therapies to treat the most common genetic form of MND and frontotemporal dementia (FTD), has secured £5 million from Northern Gritstone.